Back to the Top
Dear All,
I am trying to develop a microparticle inhalation delivery system for
local treatment of lung cancer. Basically, the compund in question is
a natural drug with known in vitro anti cancer properties. However,
its development is impeded by the fact that it is poorly bioavailable
orally.
Before proceeding to in vivo efficacy studies in a tumor induced
mouse model, it only makes sense to determine whether therapeutically
relevant cocnentration are acheived at the site of action in the
doses administered.
However, the concern I have is what should be the starting dose in
this case?
There are no clinical studies that demonstrate the anti cancer
efficacy in humans. The only study that proves its importance is one
in a mouse model where 2.5 mg/kg and 10 mg/kg of the drug is
administered intraperitoneally.
The in vitro IC50 value of the compound is 5 micromolar.
Apart from this info, I do not have any other info regarding the drug.
if anyone has any experience with area such as this, your experise
would be much appreciated..
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Therapeutically relevant concentration" as the subject | Support PharmPK by using the |
Copyright 1995-2011 David W. A. Bourne (david@boomer.org)